Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Collagen

This article was originally published in The Gray Sheet

Executive Summary

Firm receives conditional approval of an investigational device exemption to begin human studies with its Collagraft bone graft strip for the treatment of scoliosis, President and CEO Howard Palefsky announces at a May 10 session of the Alex. Brown investment conference in Baltimore. The study, which will be conducted by Collagraft marketing/clinical partner Zimmer, will include 224 subjects at 10 sites. The paste form of Collagraft was approved in May 1993 for use in long bone fractures and traumatic osseous defects, and the second generation solid strip form received approval in January
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel